Clinical Trial Imaging Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Clinical trial imaging refers to the standardized acquisition, management, analysis, and central reading of medical images generated during the conduct of clinical studies. The market is currently valued at around $1.94 billion in 2025 and is projected to grow at a compound annual rate of approximately 8.24%, reaching substantially higher levels by the end of the decade. This expansion reflects the growing reliance of sponsors on quantitative imaging endpoints to support regulatory submissions and label claims.

• •Global valuation of approximately $1.94 billion in 2025 with projected CAGR near 8.24%
• •Demand driven by imaging endpoints in oncology, neurology, and cardiovascular trials
• •Centralized imaging review and reader services are now standard in late-phase studies

Rising pharmaceutical and biotechnology R&D expenditure is the principal engine of market expansion, as sponsors conduct larger and more globally distributed trial programs. The increasing complexity of trial protocols, particularly in oncology and rare diseases, requires multi-modal imaging assessments and independent central review to reduce variability. At the same time, regulatory acceptance of imaging biomarkers as surrogate endpoints has reinforced the role of imaging across all trial phases.

• •Sustained growth in global pharma R&D and clinical trial volume
• •Greater use of imaging biomarkers and surrogate endpoints in regulatory submissions
• •Outsourcing of imaging core lab and reader services by sponsors

By modality, the market is led by computed tomography and magnetic resonance imaging, with PET, ultrasound, and X-ray also contributing meaningfully. Services such as image management, central reading, and analysis software typically represent the largest revenue share, ahead of standalone hardware. North America holds the dominant share of revenue owing to its concentration of large sponsors and trial sites, while the Asia-Pacific region is the fastest growing as China, India, and South Korea expand their clinical research capacity.

• •Services and software form the largest revenue segment, ahead of imaging hardware
• •North America leads in revenue share, supported by sponsor concentration in the United States
• •Asia-Pacific is the fastest growing region due to expanding trial activity in China and India

What are the recent trends and outlook?

Artificial intelligence and machine learning are being integrated into image acquisition, quality control, and quantitative read workflows, improving consistency across global sites. Cloud-based imaging platforms are enabling near real-time data exchange between sponsors, sites, and central readers. Decentralized and hybrid trial designs are also creating demand for imaging at community sites and the use of remote reading capabilities.

• •AI-driven image analysis is being adopted to standardize endpoint assessment across sites
• •Cloud platforms are replacing on-premise trial imaging infrastructure
• •Decentralized trial designs are broadening the use of remote reading and site-network imaging